drugset / Trial / NCT00933309

The Impact of Obesity and Obesity Treatments on Breast Cancer

NCT00933309

RandomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable dose of Avandamet that can be given in combination with exemestane to patients who are obese and postmenopausal with hormone-receptive-positive breast cancer that has spread to other parts of the body.

Timeline

Start
2009-07
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Exemestane Small molecule 25 mg Oral
Subject Metformin Small molecule 500 mg Oral
Subject Rosiglitazone Small molecule 2 mg Oral